Smaller apolipoprotein(a) isoform size and higher lipoprotein(a) concentration are independently associated with coronary heart disease, according to a Mendelian randomization analysis published in The Lancet Diabetes and Endocrinology. The author from the University of Pennsylvania in Philadelphia and colleagues concluded in their report, published online April 10 that iInterventions that lower lipoprotein(a) concentration could be more effective in reducing coronary heart disease risk in individuals who have small apolipoprotein(a) isoforms.
In an editorial of the University of Adelaide in Australia wrote, “The derivation of the findings from a large, systematic genetic analysis provides strong evidence implicating lipoprotein(a) as a causal factor in atherosclerosis.” They concluded that whether lipoprotein(a) will become a pivotal factor in our search to achieve incremental risk…
